KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Accured Expenses (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Change in Accured Expenses for 16 consecutive years, with $33.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 32.55% to $33.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.2 million, a 86.78% decrease, with the full-year FY2025 number at $6.2 million, down 86.78% from a year prior.
  • Change in Accured Expenses was $33.8 million for Q4 2025 at Halozyme Therapeutics, up from -$7.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $50.2 million in Q4 2024 to a low of -$29.7 million in Q2 2025.
  • A 5-year average of $3.3 million and a median of -$812500.0 in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: tumbled 3007.67% in 2023, then surged 629.44% in 2024.
  • Halozyme Therapeutics' Change in Accured Expenses stood at $3.5 million in 2021, then plummeted by 90.61% to $326000.0 in 2022, then crashed by 3007.67% to -$9.5 million in 2023, then soared by 629.44% to $50.2 million in 2024, then crashed by 32.55% to $33.8 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Change in Accured Expenses are $33.8 million (Q4 2025), -$7.2 million (Q3 2025), and -$29.7 million (Q2 2025).